Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Brian A Millen

Showing results (1-10 of 18) with videos related to

Pageof 2
Sort By:
Pharmaceutical Statistics|December 15, 2012
On the practical application of mixed effects models for repeated measures to clinical trial dataScott W Andersen, Brian A Millen
Journal of Biopharmaceutical Statistics|January 8, 2014
Bayesian assessment of the influence and interaction conditions in multipopulation tailoring clinical trialsBrian A Millen, Alex Dmitrienko, Guochen Song
Journal of Biopharmaceutical Statistics|April 26, 2011
Three methods for constructing parallel gatekeeping procedures in clinical trialsAlex Dmitrienko, Julia N Soulakova, Brian A Millen
Journal of Psychopharmacology (Oxford, England)|June 19, 2010
Weight changes over time in adults treated with the oral or depot formulations of olanzapine: a pooled analysis of 86 clinical trialsBrian A Millen, Giedra M Campbell, Charles M Beasley
Biometrical Journal. Biometrische Zeitschrift|November 10, 2011
Development of gatekeeping strategies in confirmatory clinical trialsAlex Dmitrienko, Brian A Millen, Thomas Brechenmacher, et al.
Psychopharmacology Bulletin|June 29, 2010
Signal detection and placebo response in schizophrenia: parallels with depressionCraig H Mallinckrodt, Lu Zhang, William R Prucka, et al.
Biological Psychiatry|April 20, 2015
Exploratory analysis for a targeted patient population responsive to the metabotropic glutamate 2/3 receptor agonist pomaglumetad methionil in schizophreniaBruce J Kinon, Brian A Millen, Lu Zhang, et al.
Therapeutic Innovation & Regulatory Science|September 22, 2018
Multipopulation Tailoring Clinical Trials: Design, Analysis, and Inference ConsiderationsBrian A Millen, Alex Dmitrienko, Sumithra J Mandrekar, et al.
Schizophrenia Research and Treatment|April 29, 2014
Pomaglumetad Methionil (LY2140023 Monohydrate) and Aripiprazole in Patients with Schizophrenia: A Phase 3, Multicenter, Double-Blind ComparisonDavid H Adams, Lu Zhang, Brian A Millen, et al.
Journal of Child and Adolescent Psychopharmacology|March 1, 2012
Comparison of long-term (at least 24 weeks) weight gain and metabolic changes between adolescents and adults treated with olanzapineLudmila A Kryzhanovskaya, Wen Xu, Brian A Millen, et al.
Pageof 2

Showing results (1-10 of 18) with videos related to

Sort By:
Pageof 2
Pharmaceutical Statistics|December 15, 2012
On the practical application of mixed effects models for repeated measures to clinical trial dataScott W Andersen, Brian A Millen
Journal of Biopharmaceutical Statistics|January 8, 2014
Bayesian assessment of the influence and interaction conditions in multipopulation tailoring clinical trialsBrian A Millen, Alex Dmitrienko, Guochen Song
Journal of Biopharmaceutical Statistics|April 26, 2011
Three methods for constructing parallel gatekeeping procedures in clinical trialsAlex Dmitrienko, Julia N Soulakova, Brian A Millen
Journal of Psychopharmacology (Oxford, England)|June 19, 2010
Weight changes over time in adults treated with the oral or depot formulations of olanzapine: a pooled analysis of 86 clinical trialsBrian A Millen, Giedra M Campbell, Charles M Beasley
Biometrical Journal. Biometrische Zeitschrift|November 10, 2011
Development of gatekeeping strategies in confirmatory clinical trialsAlex Dmitrienko, Brian A Millen, Thomas Brechenmacher, et al.
Psychopharmacology Bulletin|June 29, 2010
Signal detection and placebo response in schizophrenia: parallels with depressionCraig H Mallinckrodt, Lu Zhang, William R Prucka, et al.
Biological Psychiatry|April 20, 2015
Exploratory analysis for a targeted patient population responsive to the metabotropic glutamate 2/3 receptor agonist pomaglumetad methionil in schizophreniaBruce J Kinon, Brian A Millen, Lu Zhang, et al.
Therapeutic Innovation & Regulatory Science|September 22, 2018
Multipopulation Tailoring Clinical Trials: Design, Analysis, and Inference ConsiderationsBrian A Millen, Alex Dmitrienko, Sumithra J Mandrekar, et al.
Schizophrenia Research and Treatment|April 29, 2014
Pomaglumetad Methionil (LY2140023 Monohydrate) and Aripiprazole in Patients with Schizophrenia: A Phase 3, Multicenter, Double-Blind ComparisonDavid H Adams, Lu Zhang, Brian A Millen, et al.
Journal of Child and Adolescent Psychopharmacology|March 1, 2012
Comparison of long-term (at least 24 weeks) weight gain and metabolic changes between adolescents and adults treated with olanzapineLudmila A Kryzhanovskaya, Wen Xu, Brian A Millen, et al.
Pageof 2